The results would help in supporting the contribution of ipatasertib to the firm’s approach of combination treatment in TNBC
Reports confirms that Roche will be presenting the initial results from a study of Phase Ib that evaluates the safety and efficacy for the combination of Tecentriq, ipatasertib, and chemotherapy as a first-line treatment option for advanced triple-negative breast cancer (TNBC) patients .
The combination treatment defined an objective response rate (ORR) of 73%, regardless of tumor biomarker status.
According to Chief Medical Officer of Roche and Head of Global Product Development, Sandra Horning, MD, the company is enthusiastic about the prospective of this combination in triple-negative breast cancer, a breast cancer of aggressive type.
Roche said the results would help in supporting the contribution of ipatasertib to the firm’s approach of combination treatment in TNBC and supports its vision to evolve medicines that may benefit patients with this challenging disease, she added.
Seemingly, for the first 26 patients, these preliminary efficacy data show confirmed responses in 19/26 patients which gives a confirmed ORR of 73%. In addition, the activation of the PI3K/AKT pathway has been implicated in resistance to hormonal therapies and chemotherapies in various tumor types and loss of PTEN, a negative AKT regulator, has evolved as a probable resistance mechanism to checkpoint inhibitor therapy.
By restraining the PI3/AKT pathway, ipatasertib may allegedly lead to reversal of T-cell-mediated immunotherapy resistance. The results and the benefits which the ipatasertib and Tecentriq/taxane combination may bring to the patients are motivating and add to the development program of Roche in triple negative breast cancer, after the approval of Tecentriq combination.
In coming year, Roche will be going to initiate a crucial, randomized, multi-center, double-blind Phase III study exploring the combination of atezolizumab, paclitaxel and ipatasertib as first-line therapy for locally advanced triple-negative breast cancer.
Supposedly, ipatasertib is highly specific, oral and investigational medicine which is designed to bind and target all three AKT isoforms and helps in blocking the PI3K/AKT signaling pathway, preventing the growth and survival of cancer cells.
